{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.42","upperLimit":"0.54","value":"0.49"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"275"}],"units":"Participants"}],"description":"Survival is defined as the minimum time from study entry to requirement for additional chemotherapy and IFRT for retrieval, occurrence of a second malignant neoplasm, or death from any cause. Patients without report of such events where censored at last contact. Patients who achieve less than CR after 3 cycles of AV-PC will require IFRT and hence will satisfy this definition at the time of response evaluation. Patients who achieve a CR but who relapse will receive addition chemotherapy and IFRT or intense retrieval and hence will satisfy this definition at the time of the first relapse of Hodgkin disease. This endpoint will be used to compute event free survival without receiving radiation therapy (EFSnoRT).","dispersionType":"95% Confidence Interval","groups":[{"description":"Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim","id":"OG000","title":"Group 1"}],"paramType":"NUMBER","populationDescription":"Eligible (n=278) and evaluable response and review of response, n=275. Follow-up for censored patients (n=138) is 76 months (range: 1.8 to 108 months).","reportingStatus":"POSTED","timeFrame":"At 60 months","title":"Event Free Survival Without Receiving Radiation Therapy (EFSnoRT).","type":"PRIMARY","unitOfMeasure":"Probability of survival"}